SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial public offering of 7,000,000 shares of...
from PR Newswire: https://ift.tt/319e0yg
No comments:
Post a Comment